# SUBSTANTIAL EQUIVALENCE DETERMINATIONDECISION SUMMARYASSAY ONLY TEMPLATE

A. 510(k) Number: k113262   
B. Purpose for Submission: New device   
C. Measurand:

Cholesterol HDL- Cholesterol LDL- Cholesterol Triglycerides

D. Type of Test: Quantitative, colorimetric assay

# E. Applicant:

Alfa Wassermann Diagnostic Technologies, LLC

# F. Proprietary and Established Names:

ACE Cholesterol Reagent ACE HDL-C Reagent ACE LDL-C Reagent ACE Triglycerides Reagent

# G. Regulatory Information:

1. Regulation section:

21 CFR 862.1175: Cholesterol (total) test system   
21 CFR 862.1475: Lipoprotein test system   
21 CFR 862.1475: Lipoprotein test system   
21 CFR 862.1705: Triglyceride test system

2. Classification:

Class I (for all the four measurands), all meet limitations of exemption per 21 CFR

862.9(c)(4) and 21 CFR 862.9(c)(9)

3. Product code:

CHH: Enzymatic Esterase-Oxidase, Cholesterol   
LBS: LDL & VLDL Precipitation, Cholesterol Via Esterase-Oxidase, HDL   
MRR: System, Test, Low Density, Lipoprotein   
CDT: Lipase Hydrolysis/Glycerol Kinase Enzyme, Triglycerides

4. Panel: Clinical Chemistry (75)

# H. Intended Use:

1. Intended use(s): See indication for use below

2. Indication(s) for use:

The ACE Cholesterol Reagent is intended for the quantitative determination of cholesterol concentration in serum using the ACE Axcel Clinical Chemistry System. Cholesterol measurements are used in the diagnosis and treatment of disorders involving excess cholesterol in the blood and lipid and lipoprotein metabolism disorders. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE HDL-C Reagent is intended for the quantitative determination of high density lipoprotein cholesterol (HDL-C) concentration in serum using the ACE Axcel Clinical Chemistry System. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE LDL-C Reagent is intended for the quantitative determination of low density lipoprotein cholesterol (LDL-C) concentration in serum using the ACE Axcel Clinical Chemistry System. Lipoprotein measurements are used in the diagnosis and treatment of lipid disorders (such as diabetes mellitus), atherosclerosis, and various liver and renal diseases. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

The ACE Triglycerides Reagent is intended for the quantitative determination of triglyceride concentration in serum using the ACE Axcel Clinical Chemistry System. Triglyceride measurements are used in the diagnosis and treatment of patients with diabetes mellitus, nephrosis, liver obstruction, other diseases involving lipid metabolism or various endocrine disorders. This test is intended for use in clinical laboratories or physician office laboratories. For in vitro diagnostic use only.

3. Special conditions for use statement(s): For in vitro diagnostic use only. For prescription use.

4. Special instrument requirements:

ACE Axcel Clinical Chemistry System

# I. Device Description:

The ACE Cholesterol Reagent is composed of a single reagent bottle containing $0 . 5 \ \mathrm { m m o l / L }$ 4-Aminoantipyrine (AAP), 25 mmol/L p-Hydroxybenzoic acid, ${ > } 1 5 0$ U/L Cholesterol oxidase (Nocardia), ${ > } 2 4 0 \ \mathrm { ~ U / L }$ Cholesterol esterase (Porcine pancreas and Pseudomonas) ${ > } 1 6 0 0 \ \mathrm { U / L }$ Peroxidase (Horseradish), stabilizers, preservatives, and fillers.

The ACE HDL-C Reagent is composed of two reagent bottles (Buffer and Color Reagent). The Buffer (R1) contains: Goodâ€™s Buffer, ${ < } 1 0 0 0 ~ \mathrm { U / L }$ Cholesterol oxidase (E. coli), ${ < } 1 3 0 0$ U/L Peroxidase (Horseradish), $< 1$ mM N,N-bis(4-sulphobutyl)-m-toluidine-disodium salt (DSBmT), $< 1 \ \mathrm { \ m M }$ Accelerator, ${ < } 0 . 0 6 \%$ Preservative and ${ < } 3 0 0 0 ~ \mathrm { ~ U / L }$ Ascorbic Oxidase (Curcubita sp.). The Color Reagent (R2) contains: $< 1 5 0 0 ~ \mathrm { ~ U / L ~ }$ Cholesterol esterase (Pseudomonas sp.), ${ < } 1 \ \mathrm { m M }$ 4-Aminoantipyrine (4-AAP), $< 2 \%$ detergent and preservative.

The ACE LDL-C Reagent is composed of two reagent bottles (Buffer and Color Reagent). The Buffer (R1) contains: MES Buffer $\mathrm { ( p H } 6 . 3 )$ , $< 1 . 0 \%$ Detergent 1 $, < 1 5 0 0 ~ \mathrm { U / L }$ Cholesterol oxidase (Pseudomonas sp.), ${ < } 1 3 0 0$ ppg U/L Peroxidase (Horseradish), $< 0 . 1 \%$ 4- Aminoantipyrine (4-AAP), $< 3 0 0 0$ U/L Ascorbic acid oxidase (Curcubita sp.), $< 0 . 1 \%$ Preservative. The Color Reagent (R2) contains: MES Buffer $\mathrm { ( p H } \ 6 . 3 )$ , $< 1 . 0 \%$ Detergent 2, $< 1 . 0$ mmol/L N,N-bis(4-sulphobutyl)-m-toluidine-disodium salt (DSBmT) and $< 0 . 1 \%$ preservative.

The ACE Triglycerides Reagent is composed of a single reagent bottle. The reagent contains: $0 . 4 \mathrm { m m o l / L }$ 4-Aminoantipyrine (AAP), $2 . 6 \mathrm { m m o l / L }$ Adenosine $5 "$ -triphosphate (ATP), $3 . 0 \mathrm { m m o l / L }$ $\mathfrak { p }$ -Chlorophenol, ${ > } 2 4 0 0 \mathrm { U / L }$ Glycerol phosphate oxidase (GPO) (Microorganism), ${ > } 1 0 0 0 \ \mathrm { U / L }$ Lipase (Pseudomonas), ${ > } 5 4 0 \mathrm { U } / \mathrm { L }$ Peroxidase (Horseradish), ${ > } 4 0 0 \mathrm { U / L }$ Glycerol kinase (Cellulomonas), buffer, stabilizers and preservatives.

# J. Substantial Equivalence Information:

1. Predicate device name(s): ACE Cholesterol Reagent ACE HDL-C Reagent ACE LDL-C Reagent ACE Triglycerides Reagent

2. Predicate 510(k) number(s):

<table><tr><td rowspan=1 colspan=1>ACE Reagent Kit</td><td rowspan=1 colspan=1>Reagent 510(k)</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>k931786</td></tr><tr><td rowspan=1 colspan=1>HDL-C</td><td rowspan=1 colspan=1>k971526</td></tr><tr><td rowspan=1 colspan=1>LDL-C</td><td rowspan=1 colspan=1>k991733</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>k931786</td></tr></table>

3. Comparison with predicate:

<table><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>ACE Cholesterol Agent,(Candidate Device)</td><td rowspan=1 colspan=1>ACE Cholesterol Reagent(Predicate, k931786)</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>The ACE Cholesterol Reagent is intended forthe quantitative determination of cholesterolconcentration in serum. Cholesterolmeasurements are used in the diagnosis andtreatment of disorders involving excesscholesterol in the blood and lipid andlipoprotein metabolism disorders. For invitro diagnostic use only.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument/Platform</td><td rowspan=1 colspan=1>ACE Axcel Clinical Chemistry System</td><td rowspan=1 colspan=1>ACE ClinicalChemistry System</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Measuring Range</td><td rowspan=1 colspan=1>4 - 600 mg/dL</td><td rowspan=1 colspan=1>2 - 600 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>GEMCAL</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-BoardStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Characteristics</td><td colspan="1" rowspan="1">ACE HDL-C Agent,(Candidate Device)</td><td colspan="1" rowspan="1">ACE HDL-C Reagent(Predicate, k971526)</td></tr><tr><td colspan="1" rowspan="1">Indications forUse</td><td colspan="1" rowspan="1">The ACE HDL-C Reagent is intended for thequantitative determination of high densitylipoprotein cholesterol (HDL-C) concentration inserum. Lipoprotein measurements are used in thediagnosis and treatment of lipid disorders (such asdiabetes mellitus), atherosclerosis, and variousliver and renal diseases.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument/Platform</td><td colspan="1" rowspan="1">ACE Axcel Clinical Chemistry System</td><td colspan="1" rowspan="1">ACE ClinicalChemistry System</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reportable</td><td colspan="1" rowspan="1">8 -125 mg/dL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">GEMCAL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">CalibrationStability</td><td colspan="1" rowspan="1">30 Days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On-BoardStability</td><td colspan="1" rowspan="1">30 Days</td><td colspan="1" rowspan="1">Same</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Characteristics</td><td rowspan=1 colspan=1>ACE LDL-C Agent(Candidate Device)</td><td rowspan=1 colspan=1>ACE LDL-C Reagent(Predicate, k991733)</td></tr><tr><td rowspan=1 colspan=1>Indications forUse</td><td rowspan=1 colspan=1>The ACE LDL-C Reagent is intended forthe quantitative determination of lowdensity lipoprotein cholesterol (LDL-C)concentration in serum. Lipoproteinmeasurements are used in the diagnosisand treatment of lipid disorders (such asdiabetes mellitus), atherosclerosis, andvarious liver and renal diseases. For invitro diagnostic use only.</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Instrument/Platforms</td><td rowspan=1 colspan=1>ACE Axcel Clinical Chemistry System</td><td rowspan=1 colspan=1>ACE Clinical ChemistrySystems</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>Reportable Range</td><td rowspan=1 colspan=1>4 to 430 mg/dL</td><td rowspan=1 colspan=1>3 -500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>Calibration</td><td rowspan=1 colspan=1>ACE LDL-C Calibrators</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>CalibrationStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr><tr><td rowspan=1 colspan=1>On-BoardStability</td><td rowspan=1 colspan=1>30 Days</td><td rowspan=1 colspan=1>Same</td></tr></table>

<table><tr><td>Characteristics</td><td>ACE Triglycerides Agent (Candidate Device)</td><td>ACE Triglycerides Reagent (Predicate, k931786)</td></tr><tr><td colspan="1" rowspan="1">Indications forUse</td><td colspan="1" rowspan="1">The ACE Triglycerides Reagent isintended for quantitative determinationof triglycerides concentration in serum.It is intended for in vitro diagnostic useonly.</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Instrument/Platforms</td><td colspan="1" rowspan="1">ACE Axcel Clinical ChemistrySystem</td><td colspan="1" rowspan="1">ACE Clinical ChemistrySystems</td></tr><tr><td colspan="1" rowspan="1">Sample Type</td><td colspan="1" rowspan="1">Serum</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">Reportable Range</td><td colspan="1" rowspan="1">12 -1000 mg/dL</td><td colspan="1" rowspan="1">6 -1000 mg/dL</td></tr><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">GEMCAL</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">CalibrationStability</td><td colspan="1" rowspan="1">30 Days</td><td colspan="1" rowspan="1">Same</td></tr><tr><td colspan="1" rowspan="1">On-BoardStability</td><td colspan="1" rowspan="1">30 Days</td><td colspan="1" rowspan="1">Same</td></tr></table>

# K. Standard/Guidance Document Referenced:

CLSI EP6-A Evaluation of the Linearity of Quantitative Measurement Procedures: A Statistical Approach (2003),   
CLSI EP5-A2 Evaluation of Precision Performance of Quantitative Measurement Methods; Second Edition (2004),   
CLSI EP7-A2 Interference Testing in Clinical Chemistry; Approved Guideline; Second Edition (2005),   
CLSI EP9-A2-IR Method Comparison and Bias Estimation Using Patient Samples; Approved Guideline- Second Edition (2002),   
CLSI EP17-A Protocol for Determination of Limits of Detection; Approved Guideline (2004)

# L. Test Principle:

The ACE Cholesterol Reagent: Cholesterol esters in serum are completely hydrolyzed by cholesterol esterase to free cholesterol and free fatty acids. The cholesterol liberated by the esterase, plus any endogenous free cholesterol, are oxidized by cholesterol oxidase to yield hydrogen peroxide $\left( \mathrm { H } _ { 2 } \mathrm { O } _ { 2 } \right)$ , which then reacts oxidatively with p-hydroxybenzoic acid and 4- aminoantipyrine (AAP) in a reaction catalyzed by peroxidase, producing a red colored quinoneimine complex. The amount of chromogen formed, determined by quantitatively measuring the increase in absorbance at $5 0 5 \mathrm { n m } / 6 4 7 \mathrm { n m }$ , is directly proportional to the cholesterol concentration in the sample.

The ACE HDL-C Reagent is composed of two bottles: Buffer Reagent (R1) and Color Reagent (R2). R2 contains a unique detergent, which solubilizes only the HDL lipoprotein particles; the detergent also inhibits the reaction of the cholesterol enzymes with LDL and VLDL lipoproteins and chylomicrons by adsorbing to their surfaces. The solubilized HDL cholesterol is released and reacts with cholesterol esterase and cholesterol oxidase and a chromogen 4-Aminoantipyrine to produce a color product measurable by the increase of absorbance at $5 0 5 / 6 4 7 ~ \mathrm { n m }$ , which is directly proportional to the cholesterol concentration in the sample.

The ACE LDL-C Reagent: There are two detergents, Detergent 1 and Detergent 2, in the ACE LDL-C Reagents R1 and R2 respectively. In the first reaction, Detergent 1 solubilizes non-LDL lipoprotein particles (HDL, VLDL and chylomicrons) and releases cholesterol. The cholesterol is consumed by cholesterol esterase and cholesterol oxidase in a non-color forming reaction. In a second reaction, detergent 2 solubilizes the remaining LDL particles and forms peroxide, via the enzymes cholesterol esterase and cholesterol oxidase. The peroxide, in the presence of peroxidase and two peroxidase substrates, 4-aminoantipyrine and DSBmT, results in a purple-red color product measurable by the increase of absorbance at $5 0 5 / 6 4 7 ~ \mathrm { n m }$ , which is directly proportional to the cholesterol concentration in the sample.

The ACE Triglycerides Reagent: The ACE Triglycerides Reagent is composed of a single reagent bottle. Triglycerides in serum are hydrolyzed by lipase to form glycerol and free fatty acids. In the presence of adenosine triphosphate (ATP) and glycerol kinase (GK), the glycerol is converted to glycerol-I-phosphate (G-I-P) and the ATP to adenosine diphosphate (ADP). Glycerol-I-phosphate is oxidized by glycerol phosphate oxidase (GPO) to yield hydrogen peroxide $\left( \mathrm { H } _ { 2 } \mathrm { O } _ { 2 } \right)$ . The hydrogen peroxide then acts to oxidatively couple pchlorophenol and 4-aminoantipyrine (AAP) in a reaction catalyzed by peroxidase, producing a red colored quinoneimine complex which absorbs strongly at $5 0 5 \mathrm { n m }$ .

# M. Performance Characteristics (if/when applicable):

1. Analytical performance:

a. Precision/Reproducibility:

In-House: ACE Cholesterol Reagent Three serum based pools and one normal human serum sample, were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 20 or more days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 87.7 mg/dLCholesterol</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.6%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>1.8%</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Sample 2Mean 261.5 mg/dLCholesterol</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation, mg/dL</td><td colspan="1" rowspan="1">4.2</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">4.3</td></tr><tr><td colspan="1" rowspan="1">Coefficient of Variation</td><td colspan="1" rowspan="1">1.6%</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.3%</td><td colspan="1" rowspan="1">1.6%</td></tr><tr><td colspan="1" rowspan="1">Sample 3Mean 430.4 mg/dLCholesterol</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation, mg/dL</td><td colspan="1" rowspan="1">8.7</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">3.7</td><td colspan="1" rowspan="1">9.4</td></tr><tr><td colspan="1" rowspan="1">Coefficient of Variation</td><td colspan="1" rowspan="1">2.0%</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">0.9%</td><td colspan="1" rowspan="1">2.2%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 176.4 mg/dLCholesterol</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.8%</td></tr></table>

# Point of Care Laboratory: ACE Cholesterol Reagent

Three serum based pools were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=3>Cholesterol</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Meanmg/dL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>84.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>89.3</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>85.3</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>255.6</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>270.3</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>3.3</td><td rowspan=1 colspan=1>1.2</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>256.4</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>423.6</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>441.6</td><td rowspan=1 colspan=1>5.1</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>1.4</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>423.2</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>1.6</td></tr></table>

# In-House: ACE HDL-C Reagent

Three serum based pools and one normal human serum sample, were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 20 or more days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 27.8 mg/dL HDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>2.3%</td><td rowspan=1 colspan=1>3.4%</td><td rowspan=1 colspan=1>4.8%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean 63.0 mg/dL HDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>3.0%</td><td rowspan=1 colspan=1>3.4%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3Mean 98.3 mg/dL HDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>3.1</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.7%</td><td rowspan=1 colspan=1>1.3%</td><td rowspan=1 colspan=1>2.4%</td><td rowspan=1 colspan=1>3.2%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 73.9 mg/dL HDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.4%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>3.2%</td></tr></table>

# Point of Care Laboratory: ACE HDL-C Reagent

Three serum based pools were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td colspan="3" rowspan="1">HDL-C</td><td colspan="2" rowspan="1">Within Run</td><td colspan="2" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Lab</td><td colspan="1" rowspan="1">Sample</td><td colspan="1" rowspan="1">Meanmg/dL</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td><td colspan="1" rowspan="1">SD</td><td colspan="1" rowspan="1">%CV</td></tr><tr><td colspan="1" rowspan="1">POL 1</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">25.8</td><td colspan="1" rowspan="1">0.4</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">2.3</td></tr><tr><td colspan="1" rowspan="1">POL 2</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">27.0</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">2.6</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">3.5</td></tr><tr><td colspan="1" rowspan="1">POL 3</td><td colspan="1" rowspan="1">1</td><td colspan="1" rowspan="1">26.8</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">2.2</td><td colspan="1" rowspan="1">0.8</td><td colspan="1" rowspan="1">3.0</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">POL 1</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">59.4</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.1</td></tr><tr><td colspan="1" rowspan="1">POL 2</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">61.5</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.3</td><td colspan="1" rowspan="1">2.2</td></tr><tr><td colspan="1" rowspan="1">POL 3</td><td colspan="1" rowspan="1">2</td><td colspan="1" rowspan="1">31.3</td><td colspan="1" rowspan="1">0.6</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">1.8</td></tr><tr><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td><td colspan="1" rowspan="1"></td></tr><tr><td colspan="1" rowspan="1">POL 1</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">93.5</td><td colspan="1" rowspan="1">1.0</td><td colspan="1" rowspan="1">1.1</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.7</td></tr><tr><td colspan="1" rowspan="1">POL 2</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">97.6</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.6</td><td colspan="1" rowspan="1">1.9</td><td colspan="1" rowspan="1">1.9</td></tr><tr><td colspan="1" rowspan="1">POL 3</td><td colspan="1" rowspan="1">3</td><td colspan="1" rowspan="1">97.0</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">2.1</td><td colspan="1" rowspan="1">2.1</td></tr></table>

# In-House: ACE LDL-C Reagent

Three serum based pools and one normal human serum sample, were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 20 or more days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 45.1 mg/dL LDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>2.2</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>4.6%</td><td rowspan=1 colspan=1>1.2%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>4.9%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean 181.7 mg/dLLDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>4.7</td><td rowspan=1 colspan=1>3.2</td><td rowspan=1 colspan=1>3.4</td><td rowspan=1 colspan=1>6.6</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>2.6%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.9%</td><td rowspan=1 colspan=1>3.6%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 3Mean 328.5 mg/dLLDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>0.0</td><td rowspan=1 colspan=1>6.1</td><td rowspan=1 colspan=1>10.6</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>2.7%</td><td rowspan=1 colspan=1>0.0%</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>3.2%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 4Mean 86.3 mg/dL LDL-C</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>3.0</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>2.5%</td><td rowspan=1 colspan=1>2.2%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>3.5%</td></tr></table>

# Point of Care Laboratory: ACE LDL-C Reagent

Three serum-based pools were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

In-House: ACE Triglycerides Reagent   

<table><tr><td rowspan=1 colspan=3>LDL-C</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Meanmg/dL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>45.9</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>4.6</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>41.9</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.9</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>46.0</td><td rowspan=1 colspan=1>1.9</td><td rowspan=1 colspan=1>4.1</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>5.2</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>185.9</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>2.6</td><td rowspan=1 colspan=1>7.0</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>164.0</td><td rowspan=1 colspan=1>6.2</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>8.2</td><td rowspan=1 colspan=1>5.0</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>180.9</td><td rowspan=1 colspan=1>3.7</td><td rowspan=1 colspan=1>2.0</td><td rowspan=1 colspan=1>4.9</td><td rowspan=1 colspan=1>2.7</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>336.7</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>8.0</td><td rowspan=1 colspan=1>2.4</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>307.6</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>2.2</td><td rowspan=1 colspan=1>10.5</td><td rowspan=1 colspan=1>3.4</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>328.7</td><td rowspan=1 colspan=1>5.7</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>2.6</td></tr></table>

Three serum-based pools and one normal human serum sample were tested on one ACE Axcel Clinical Chemistry System two times per run, two runs per day, for a total of 20 or more days. The results are summarized in the table below:

<table><tr><td rowspan=1 colspan=1>Sample 1Mean 73.3 mg/dLTriglycerides</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>1.3</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>1.0%</td><td rowspan=1 colspan=1>0.5%</td><td rowspan=1 colspan=1>2.1%</td></tr></table>

<table><tr><td rowspan=1 colspan=1>Sample 2Mean 138.9 mg/dLTriglycerides</td><td rowspan=1 colspan=1>WithinRun</td><td rowspan=1 colspan=1>BetweenRun</td><td rowspan=1 colspan=1>BetweenDay</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Standard Deviation, mg/dL</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>2.9</td></tr><tr><td rowspan=1 colspan=1>Coefficient of Variation</td><td rowspan=1 colspan=1>1.8%</td><td rowspan=1 colspan=1>0.8%</td><td rowspan=1 colspan=1>0.6%</td><td rowspan=1 colspan=1>2.1%</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Sample 3Mean 950.4 mg/dLTriglycerides</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation, mg/dL</td><td colspan="1" rowspan="1">11.5</td><td colspan="1" rowspan="1">7.4</td><td colspan="1" rowspan="1">9.6</td><td colspan="1" rowspan="1">16.7</td></tr><tr><td colspan="1" rowspan="1">Coefficient of Variation</td><td colspan="1" rowspan="1">1.2%</td><td colspan="1" rowspan="1">0.8%</td><td colspan="1" rowspan="1">1.0%</td><td colspan="1" rowspan="1">1.8%</td></tr><tr><td colspan="1" rowspan="1">Sample 4Mean 58.6 mg/dLTriglycerides</td><td colspan="1" rowspan="1">WithinRun</td><td colspan="1" rowspan="1">BetweenRun</td><td colspan="1" rowspan="1">BetweenDay</td><td colspan="1" rowspan="1">Total</td></tr><tr><td colspan="1" rowspan="1">Standard Deviation, mg/dL</td><td colspan="1" rowspan="1">1.7</td><td colspan="1" rowspan="1">0.7</td><td colspan="1" rowspan="1">0.0</td><td colspan="1" rowspan="1">1.8</td></tr><tr><td colspan="1" rowspan="1">Coefficient of Variation</td><td colspan="1" rowspan="1">2.9%</td><td colspan="1" rowspan="1">1.3%</td><td colspan="1" rowspan="1">0.0%</td><td colspan="1" rowspan="1">3.2%</td></tr></table>

# Point of Care Laboratory: ACE Triglycerides Reagent

Four serum-based pools were tested on three ACE Axcel Clinical Chemistry Systems (one at each POL site) at least three times per run, one run per day, for a total of 5 days. The mean, standard deviations and $\%$ coefficients of variation (CV) were calculated for each sample.

<table><tr><td rowspan=1 colspan=3>Triglycerides</td><td rowspan=1 colspan=2>Within Run</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Meanmg/dL</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td><td rowspan=1 colspan=1>SD</td><td rowspan=1 colspan=1>%CV</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>70.5</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>2.3</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>73.0</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>72.7</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>4.1</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>136.0</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>1.7</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>137.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>1.8</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>136.5</td><td rowspan=1 colspan=1>1.6</td><td rowspan=1 colspan=1>1.2</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>1.3</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>182.1</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>4.6</td><td rowspan=1 colspan=1>2.5</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>185.4</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>1.5</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>182.1</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.6</td><td rowspan=1 colspan=1>1.1</td><td rowspan=1 colspan=1>0.6</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>933.4</td><td rowspan=1 colspan=1>4.3</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>6.4</td><td rowspan=1 colspan=1>0.7</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>933.4</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.9</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>1.0</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>944.0</td><td rowspan=1 colspan=1>7.8</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>16.6</td><td rowspan=1 colspan=1>1.8</td></tr></table>

# b. Linearity/assay reportable range:

ACE Cholesterol Reagent Linearity studies were carried out using dilutions of a spiked serum samples. Eleven concentrations were prepared by mixing spiked serum samples in known proportion

with blank samples. All samples were measured in triplicate. The sample range tested was 3 to $9 6 6 \mathrm { m g / d L }$ .

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>$b2}$</td></tr><tr><td rowspan=1 colspan=1>4 to 600 mg/dL</td><td rowspan=1 colspan=1>-1.1</td><td rowspan=1 colspan=1>1.016</td><td rowspan=1 colspan=1>0.9993</td></tr></table>

Based on the linearity data, the measuring range claimed from 4 to $6 0 0 ~ \mathrm { m g / d L }$ was supported.

# ACE HDL-C Reagent

Linearity studies were carried out using dilutions of a spiked serum samples. Eleven concentrations were prepared by mixing spiked serum samples in known proportion with blank samples. All samples were measured in triplicate. The sample range tested was 7.6 to $1 3 7 . 7 \mathrm { m g / d L }$ .

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>$r2}$</td></tr><tr><td rowspan=1 colspan=1>8 to125 mg/dL</td><td rowspan=1 colspan=1>0.1</td><td rowspan=1 colspan=1>1.011</td><td rowspan=1 colspan=1>0.9986</td></tr></table>

Based on the linearity data, the measuring range claimed from 8 to $1 2 5 ~ \mathrm { m g / d L }$ was supported.

# ACE LDL-C Reagent

Linearity studies were carried out using dilutions of a spiked serum samples. Eleven concentrations were prepared by mixing spiked serum samples in known proportion with blank samples. All samples were measured in triplicate. The sample range tested was 0.3 to $4 3 0 \mathrm { m g / d L }$ .

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>r2}$</td></tr><tr><td rowspan=1 colspan=1>4 to 430 mg/dL</td><td rowspan=1 colspan=1>-4.5</td><td rowspan=1 colspan=1>0.985</td><td rowspan=1 colspan=1>0.9981</td></tr></table>

Based on the linearity data, the measuring range claimed from 4 to $4 3 0 \mathrm { m g / d L }$ was supported.

# ACE Triglycerides Reagent

Linearity studies were carried out using dilutions of a spiked serum samples. Eleven concentrations were prepared by mixing spiked serum samples in known proportion with blank samples. All samples were measured in triplicate. The sample range tested was 12.3 to $1 2 4 9 . 3 ~ \mathrm { m g / d L }$ .

<table><tr><td rowspan=1 colspan=1>Claimed Measuring Range</td><td rowspan=1 colspan=1>Intercept</td><td rowspan=1 colspan=1>Slope</td><td rowspan=1 colspan=1>b2}$</td></tr><tr><td rowspan=1 colspan=1>12 to 1000 mg/dL</td><td rowspan=1 colspan=1>8.6</td><td rowspan=1 colspan=1>0.9915</td><td rowspan=1 colspan=1>0.9995</td></tr></table>

Based on the linearity data, the measuring range claimed from 12 to $8 5 0 ~ \mathrm { m g / d L }$ was supported.

c. Traceability, Stability, Expected values (controls, calibrators, or methods):

Traceability   
ACE Cholesterol Reagent is traceable to NIST SRM 1951. The calibrator (GEMCAL) was previously cleared under k931786.

ACE HDL-C Reagent is traceable to a CDC certified method. The calibrator (GEMCAL) was previously cleared under k931786.

ACE LDL-C Reagent is traceable to the CDC LDL cholesterol reference method. The ACE LDL-C Calibrators were previously cleared under k931733.

ACE Triglycerides Reagents is traceable to NIST SRM 1951. The calibrator (GEMCAL) was previously cleared under k931786

# On-Board stability:

The stability protocols and acceptance criteria were reviewed and determined to be adequate. All ACE reagent in this submission demonstrated on-board stability of 30 days.

The real-time close-vial stability study protocols and acceptance criteria were reviewed and determined to be adequate. The stability for each reagent is shown in the table below:

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Closed-Vial Stability(months)</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>15</td></tr><tr><td rowspan=1 colspan=1>HDL-C</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>LDL-C</td><td rowspan=1 colspan=1>24</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>15</td></tr></table>

# d. Detection limit:

Protocols for the determination of the limit of the blank (LoB) and the limit of detection (LoD) were performed in accordance with the recommendations in the CLSI Guideline EP17-A. Testing was carried out using true blanks and low level samples (total 60 each) over three days on two ACE Axcel Clinical Chemistry Systems.

The resulting LoB and LoD for the four measurands are summarized below:

<table><tr><td rowspan=1 colspan=1>Reagent</td><td rowspan=1 colspan=1>Limit of Blank(LoB)</td><td rowspan=1 colspan=1>Limit of Detection(LoD)</td></tr><tr><td rowspan=1 colspan=1>Cholesterol</td><td rowspan=1 colspan=1>2.9 mg/dL</td><td rowspan=1 colspan=1>3.6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>HDL-C</td><td rowspan=1 colspan=1>1.0 mg/dL</td><td rowspan=1 colspan=1>1.5 mg/dL</td></tr><tr><td rowspan=1 colspan=1>LDL-C</td><td rowspan=1 colspan=1>2.7mg/dL</td><td rowspan=1 colspan=1>3.9mg/dL</td></tr><tr><td rowspan=1 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>10.4mg/dL</td><td rowspan=1 colspan=1>11.6 mg/dL</td></tr></table>

# ACE Cholesterol Reagent

Interference studies were performed by using serum pools containing Cholesterol with individual interferents at a range of concentrations. The sera were assayed for Cholesterol $\mathbf { \tilde { n } } = 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed $6 \mathrm { y } \pm 1 0 \%$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Cholesterol ConcentrationsTested (mg/dL)</td><td rowspan=1 colspan=1>No SignificantInterference At or Below:</td></tr><tr><td rowspan=2 colspan=1>UnconjugatedBilirubin</td><td rowspan=1 colspan=1>Low Pool: 182</td><td rowspan=2 colspan=1>30 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 405</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Low Pool: 159</td><td rowspan=2 colspan=1>500 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 445</td></tr><tr><td rowspan=2 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>Low Pool: 170</td><td rowspan=2 colspan=1>2180 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 378</td></tr><tr><td rowspan=2 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>Low Pool: 185</td><td rowspan=2 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 417</td></tr></table>

# ACE HDL-C Reagent:

Interference studies were performed by using serum pools containing HDL with individual interferents at a range of concentrations. The sera were assayed for HDL $( { \mathfrak { n } } =$ 3 replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed b $y \pm 1 0 \%$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td colspan="1" rowspan="1">Interferent</td><td colspan="1" rowspan="1">HDL ConcentrationsTested (mg/dL)</td><td colspan="1" rowspan="1">No SignificantInterference At or Below:</td></tr><tr><td colspan="1" rowspan="2">UnconjugatedBilirubin</td><td colspan="1" rowspan="1">Low Pool: 43</td><td colspan="1" rowspan="2">59 mg/dL</td></tr><tr><td colspan="1" rowspan="1">High Pool: 98</td></tr><tr><td colspan="1" rowspan="2">Hemoglobin</td><td colspan="1" rowspan="1">Low Pool: 64</td><td colspan="1" rowspan="2">1000 mg/dL</td></tr><tr><td colspan="1" rowspan="1">High Pool: 91</td></tr><tr><td colspan="1" rowspan="2">Triglycerides</td><td colspan="1" rowspan="1">Low Pool: 30</td><td colspan="1" rowspan="2">652 mg/dL</td></tr><tr><td colspan="1" rowspan="1">High Pool: 101</td></tr><tr><td colspan="1" rowspan="2">Ascorbic Acid</td><td colspan="1" rowspan="1">Low Pool: 45</td><td colspan="1" rowspan="2">6 mg/dL</td></tr><tr><td colspan="1" rowspan="1">High Pool: 105</td></tr></table>

# ACE LDL-C Reagent:

Interference studies were performed by using serum pools containing LDL with individual interferents at a range of concentrations. The sera were assayed for LDL $( { \mathfrak { n } } ^ { = }$ 3 replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed $6 \mathrm { y } \pm 1 0 \%$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>LDL ConcentrationsTested (mg/dL)</td><td rowspan=1 colspan=1>No SignificantInterference At or Below:</td></tr><tr><td rowspan=2 colspan=1>UnconjugatedBilirubin</td><td rowspan=1 colspan=1>Low Pool: 116</td><td rowspan=2 colspan=1>59 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 374</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Low Pool: 74</td><td rowspan=2 colspan=1>1000 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 273</td></tr><tr><td rowspan=2 colspan=1>Triglycerides</td><td rowspan=1 colspan=1>Low Pool: 113</td><td rowspan=2 colspan=1>1233 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 352</td></tr><tr><td rowspan=2 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>Low Pool: 122</td><td rowspan=2 colspan=1>6 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 396</td></tr></table>

# ACE Triglycerides Reagent:

Interference studies were performed by using serum pools containing Triglycerides with individual interferents at a range of concentrations. The sera were assayed for Triglycerides $\mathrm { \Delta } _ { \mathrm { n } } = 3$ replicates) and the mean result calculated. Interference was considered to be significant by the sponsor if the analyte recovery changed $6 \mathrm { y } \pm 1 0 \%$ . The results reported were obtained on the ACE Axcel Clinical Chemistry System analyzer.

<table><tr><td rowspan=1 colspan=1>Interferent</td><td rowspan=1 colspan=1>Triglycerides ConcentrationsTested (mg/dL)</td><td rowspan=1 colspan=1>No Significant InterferenceAt or Below:</td></tr><tr><td rowspan=2 colspan=1>UnconjugatedBilirubin</td><td rowspan=1 colspan=1>Low Pool: 78</td><td rowspan=2 colspan=1>7 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 726</td></tr><tr><td rowspan=2 colspan=1>Hemoglobin</td><td rowspan=1 colspan=1>Low Pool: 50</td><td rowspan=2 colspan=1>125 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 270</td></tr><tr><td rowspan=2 colspan=1>Ascorbic Acid</td><td rowspan=1 colspan=1>Low Pool: 75</td><td rowspan=2 colspan=1>0.75 mg/dL</td></tr><tr><td rowspan=1 colspan=1>High Pool: 716</td></tr></table>

The following limitations are stated in the labeling for ACE Triglyceride Reagent:

â€œUse clear, unhemolyzed serum. Hemolyzed and icteric samples cannot be used.â€ â€œAdvice patients not to take any alcohol or vitamin supplements 24 hours prior to fasting blood work.â€

f. Assay cut-off: Not applicable   
g. Cleaning and Disinfection Not applicable.

2. Comparison studies: Studies were carried out according to CLSI EP09-A2-IR.

In house: ACE Cholesterol Reagent

One hundred ten serum samples were assayed in parallel by both the test and predicate methods. The results were analyzed by using Deming regression. The range tested was 7 to $5 2 7 \mathrm { n g / d L }$ . Altered samples were included in the study (no more than $10 \%$ ).

The comparison by Deming regression resulted in a slope of 1.012 $( 9 5 \% C \mathrm { I } = 0 . 9 9 9$ to 1.026), an intercept of -3.3 $9 5 \% C \mathrm { I } = - 6 . 2$ to -0.5), correlation coefficient $( \mathrm { R } ^ { 2 } ) = 0 . 9 9 7 7 .$ , and a standard error of 5.0.

Point of Care Laboratory: ACE Cholesterol Reagent   
Serum samples were assayed in parallel by both the test and predicate methods at three   
POC sites. The results were analyzed by using Deming regression. (Some altered   
samples were used among all three sites.)

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>57</td><td rowspan=1 colspan=1>22-571</td><td rowspan=1 colspan=1>Y = 1.003x- 2.7</td><td rowspan=1 colspan=1>0.9995</td><td rowspan=1 colspan=1>3.0</td><td rowspan=1 colspan=1>0.995 to1.012</td><td rowspan=1 colspan=1>-4.6 to -0.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>17-515</td><td rowspan=1 colspan=1>Y = 1.017x- 1.9</td><td rowspan=1 colspan=1>0.9978</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>0.999 to1.034</td><td rowspan=1 colspan=1>-6.1 to 2.3</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>46</td><td rowspan=1 colspan=1>62-538</td><td rowspan=1 colspan=1>y = 0.996x -0.3</td><td rowspan=1 colspan=1>0.9945</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>0.964 to1.028</td><td rowspan=1 colspan=1>-7.3 to 6.7</td></tr></table>

# In house: ACE HDL-C Reagent

One hundred eight serum samples were assayed in parallel by both the test and predicate methods. The results were analyzed by using Deming regression. The range tested was 8 to $1 2 2 { \mathrm { n g / d L } }$ . Altered samples were included in the study (no more than $10 \%$ ).

The comparison by Deming regression resulted in a slope of 0.972 $( 9 5 \% C ] = 0 . 9 5 6 4$ to 0.989), an intercept of 0.5 $9 5 \% C \mathrm { I } = - 0 . 4$ to 1.5), correlation coefficient $( \mathrm { R } ^ { 2 } ) = 0 . 9 9 5 7$ , and a standard error of 1.7.

# Point of Care Laboratory: ACE HDL-C Reagent

Serum samples were assayed in parallel by both the test and predicate methods at three POC sites. The results were analyzed by using Deming regression. Some altered samples were used among all three sites.

<table><tr><td rowspan=1 colspan=1>Lab</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>POL 1</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>13-110</td><td rowspan=1 colspan=1>y = 0.959x- 2.6</td><td rowspan=1 colspan=1>0.9961</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.937 to0.981</td><td rowspan=1 colspan=1>-4.0 to -1.3</td></tr><tr><td rowspan=1 colspan=1>POL 2</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>20-110</td><td rowspan=1 colspan=1>y = 0.969x- 1.8</td><td rowspan=1 colspan=1>0.9964</td><td rowspan=1 colspan=1>1.7</td><td rowspan=1 colspan=1>0.947 to0.991</td><td rowspan=1 colspan=1>-3.1 to -0.4</td></tr><tr><td rowspan=1 colspan=1>POL 3</td><td rowspan=1 colspan=1>43</td><td rowspan=1 colspan=1>21-117</td><td rowspan=1 colspan=1>y= 1.015x- 0.5</td><td rowspan=1 colspan=1>0.9898</td><td rowspan=1 colspan=1>2.4</td><td rowspan=1 colspan=1>0.970 to1.061</td><td rowspan=1 colspan=1>-3.0 to 2.0</td></tr></table>

# In house: ACE LDL-C Reagent

One hundred eight serum samples were assayed in parallel by both the test and predicate methods and the results were analyzed by using Deming regression. The range tested was 32 to $4 2 2 \mathrm { n g / d L }$ . Altered samples were included in the study (no more than $10 \%$ ).

The comparison by Deming regression resulted in a slope of 0.982 $( 9 5 \% C \mathrm { I } = 0 . 9 6 8$ to 0.996), an intercept of -1.0 $9 5 \% C \mathrm { I } = - 3 . 1$ to 1.0), correlation coefficient $( \mathrm { R } ^ { 2 } ) = 0 . 9 9 7 3$ , and a standard error of 4.7.

# Point of Care Laboratory: ACE LDL-C Reagent

Serum samples were assayed in parallel by both the test and predicate methods at three POC sites. The results were analyzed by using Deming regression. Some altered samples were used among all three sites.

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>74</td><td rowspan=1 colspan=1>4-395</td><td rowspan=1 colspan=1>y = 1.012x+1.4</td><td rowspan=1 colspan=1>0.9970</td><td rowspan=1 colspan=1>6.0</td><td rowspan=1 colspan=1>0.994 to1.031</td><td rowspan=1 colspan=1>-1.3 to 4.0</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>9-397</td><td rowspan=1 colspan=1>y = 1.010x -2.5</td><td rowspan=1 colspan=1>0.9974</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.991 to1.030</td><td rowspan=1 colspan=1>-5.5 to 0.4</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>30-417</td><td rowspan=1 colspan=1>y = 1.037x -3.2</td><td rowspan=1 colspan=1>0.9940</td><td rowspan=1 colspan=1>9.0</td><td rowspan=1 colspan=1>1.002 to1.071</td><td rowspan=1 colspan=1>-8.4 to 2.1</td></tr></table>

# In house: ACE Triglycerides Reagent

One hundred eleven serum samples were assayed in parallel by both the test and predicate methods and the results compared by Deming regression. The range tested was 24 to $9 7 5 ~ \mu \mathrm { g / d L }$ . Altered samples were included in the study (no more than $10 \%$ ).

The comparison by Deming regression resulted in a slope of 1.031 $( 9 5 \% C \mathrm { I } = 1 . 0 2 5$ to 1.037), an intercept of -0.8 $9 5 \% C \mathrm { I } = - 2 . 7$ to 1.1), correlation coefficient $( \mathrm { R } ^ { 2 } ) = 0 . 9 9 9 5$ , and a standard error of 6.6.

# Point of Care Laboratory: ACE Triglycerides Reagent

Serum samples were assayed in parallel by both the test and predicate methods at three POC sites. The results were analyzed by using Deming regression. Some altered samples were used among all three sites.

<table><tr><td rowspan=1 colspan=1>POL</td><td rowspan=1 colspan=1>N</td><td rowspan=1 colspan=1>Range</td><td rowspan=1 colspan=1>RegressionEquation</td><td rowspan=1 colspan=1>CorrelationCoefficient</td><td rowspan=1 colspan=1>StandardError</td><td rowspan=1 colspan=1>ConfidenceIntervalSlope</td><td rowspan=1 colspan=1>ConfidenceIntervalIntercept</td></tr><tr><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>54</td><td rowspan=1 colspan=1>23-976</td><td rowspan=1 colspan=1>y = 1.008x -1.6</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>1.000 to1.016</td><td rowspan=1 colspan=1>-3.9 to 0.7</td></tr><tr><td rowspan=1 colspan=1>2</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>20-910</td><td rowspan=1 colspan=1>y = 0.997x -4.0</td><td rowspan=1 colspan=1>0.9996</td><td rowspan=1 colspan=1>5.9</td><td rowspan=1 colspan=1>0.989 to1.004</td><td rowspan=1 colspan=1>-6.3 to -1.7</td></tr><tr><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>47</td><td rowspan=1 colspan=1>37-978</td><td rowspan=1 colspan=1>y = 1.012x -2.8</td><td rowspan=1 colspan=1>0.9992</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>1.000 to1.024</td><td rowspan=1 colspan=1>-6.3 to 0.6</td></tr></table>

3. Clinical studies: Not applicable

4. Clinical cut-off: Not applicable

5. Expected values/Reference range:

Cholesterol: Desirable: ${ < } 2 0 0 \ \mathrm { m g / d L }$ , Borderline: $2 0 0 { - } 2 3 9 \mathrm { m g / d L }$ , High: ${ > } 2 3 9 \mathrm { m g / d L } )$ )   
HDL: $< 4 0 \mathrm { m g / d L } = \mathrm { L o w } _ { \mathrm { ; } }$ , $\geq 6 0 \mathrm { m g / d L } = \mathrm { H i g h }$   
LDL: Optimal: ${ < } 1 0 0 \ \mathrm { m g / d L }$ , Near optimal: $1 0 0 - 1 2 9 \mathrm { m g / d L }$ , Borderline high: 130 $- 1 5 9 \mathrm { m g / d L }$ , High: 160 â€“ 189, Very high: ${ > } 1 8 9 \ \mathrm { m g / d L }$   
Triglycerides: ${ < } 1 5 0 =$ normal, $1 5 0 - 1 9 9 =$ borderline high, $2 0 0 { - } 4 9 9 = 1$ high, $\geq 5 0 0 =$ very high

NCEP, Third Report of National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Cholesterol in Adults (Adult Treatment Panel III); Executive Summary. NIH Publication No. 02-5215. National Institutes of Health. Bethesda, Maryland: September 2002.

# N. Proposed Labeling:

The labeling is sufficient and it satisfies the requirements of 21 CFR Part 809.10.

# O. Conclusion:

The submitted information in this premarket notification is complete and supports a substantial equivalence decision.